论文部分内容阅读
目的 :探讨纤溶酶原激活物抑制物 1(PAI 1)与冠心病及其不同临床亚型的相关性及其与冠状动脉病变程度的关系。方法 :选择 345例非糖尿病的住院患者 (其中 2 95例已行冠状动脉造影 ) ,分为对照组和冠心病组 ,测定血浆PAI 1抗原水平。结果 :血浆PAI 1抗原水平在对照组与冠心病组间无统计学差异。与稳定型心绞痛组 (SAP)相比 ,不稳定型心绞痛 (UAP)患者PAI 1水平显著升高 [(2 5 .0± 7.2 ) μg/L比 (2 2 .3± 7.1) μg/L ,P <0 .0 5 ],经Logistic回归分析 ,PAI 1水平与UAP仍有显著性相关 ,调整后的OR值为1.83(P <0 .0 5 )。PAI 1血浆水平与冠状动脉病变支数无关。结论 :血浆PAI 1抗原水平升高可能与UAP有关 ,但与冠心病的发生无关 ,且对冠状动脉病变范围无预测价值。
Objective: To investigate the correlation between plasminogen activator inhibitor 1 (PAI 1) and coronary heart disease (CHD) and their clinical subtypes and its relationship with the degree of coronary artery lesion. Methods: A total of 345 inpatients with nondiabetic conditions (2 95 cases of whom had coronary angiography) were divided into control group and coronary heart disease group. Plasma PAI 1 antigen level was determined. Results: Plasma PAI 1 antigen levels in the control group and coronary heart disease group was no significant difference. PAI-1 levels in patients with unstable angina pectoris (UAP) were significantly higher than those in patients with stable angina (SAP) [(2.5 ± 7.2) μg / L vs (22.3 ± 7.1) μg / L, P <0.05]. Logistic regression analysis showed that the level of PAI-1 was still significantly correlated with UAP. The adjusted OR was 1.83 (P <0.05). PAI 1 plasma levels have no correlation with coronary artery lesion count. CONCLUSION: The plasma PAI 1 level may be related to UAP, but not to the occurrence of coronary heart disease, and has no predictive value on the extent of coronary artery disease.